If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 197.50
Bid: 195.00
Ask: 200.00
Change: 42.50 (27.42%)
Spread: 5.00 (2.564%)
Open: 155.00
High: 197.50
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of options

27 Oct 2023 07:15

RNS Number : 4718R
Faron Pharmaceuticals Oy
27 October 2023
 

Faron Pharmaceuticals Ltd.

 

("Faron")

 

Exercise of options

Issue of equity

 

Company announcement, October 27, 2023 at 7:15 a.m. BST / 9:15 a.m. EEST

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical- stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that it has received notifications from option holders to exercise 2015B options over 22,306 in the Company at an exercise price of EUR 2.90 (approx. GBP 2.48) per share and 2015D options over 25,873 shares in the Company at an exercise price of EUR 1.09 (approx. GBP 0.93) per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the Company's website at https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf.

 

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth Market, respectively. Admission of the New Ordinary Shares is expected to occur on or around October 30, 2023 following issue and registration of the New Ordinary Shares on or around October 31, 2023 ("Registration"). The New Ordinary Shares will rank pari passu with existing ordinary shares.

 

Faron's enlarged issued number of shares immediately following Registration will be 68,786,699 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, Registration, the total number of voting rights in Faron will be 68,786,699. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.

 

For more information please contact: 

 

Investor Contact 

LifeSci Advisors? 

Daniel Ferry? 

Managing Director? 

daniel@lifesciadvisors.com? 

+1 (617) 430-7576? 

  

Cairn Financial Advisers LLP, Nomad 

Sandy Jamieson, Jo Turner 

Phone: +44 (0) 207 213 0880 

  

Peel Hunt LLP, Broker 

Christopher Golden, James Steel 

Phone: +44 (0) 20 7418 8900 

  

Sisu Partners Oy, Certified Adviser on Nasdaq First North 

Juha Karttunen 

Phone: +358 (0)40 555 4727 

Jukka Järvelä 

Phone: +358 (0)50 553 8990 

 

About Faron Pharmaceuticals Ltd.? 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is?bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function.?Bexmarilimab?is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at?www.faron.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBQLLLXBLEFBZ
Date   Source Headline
18th Feb 202011:00 amRNSPrice Monitoring Extension
18th Feb 20209:05 amRNSSecond Price Monitoring Extn
18th Feb 20209:00 amRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTraumakine update
27th Jan 20207:00 amRNSOvarian cancer selected as 2nd MATINS trial cohort
13th Jan 20207:00 amRNSDMC approves colorectal cancer cohort expansion
30th Dec 20199:30 amRNSUpdate on Traumakine drug substance manufacturing
12th Dec 20192:00 pmRNSPrice Monitoring Extension
11th Dec 20197:00 amRNSMatins Trial Update
2nd Dec 20192:06 pmRNSSecond Price Monitoring Extn
2nd Dec 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20192:05 pmRNSSecond Price Monitoring Extn
29th Nov 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20197:31 amRNSLIQUIDITY PROVIDING AGREEMENT
29th Nov 20197:30 amRNSCompany Description & information on cash position
28th Nov 20199:05 amRNSSecond Price Monitoring Extn
28th Nov 20199:00 amRNSPrice Monitoring Extension
28th Nov 20197:00 amRNSFDA has approved Faron's Clevegen IND
27th Nov 20194:00 pmRNSFaron´s financial calendar for 2020
21st Nov 20192:00 pmRNSHoldings in Company
21st Nov 20199:00 amRNSPrice Monitoring Extension
21st Nov 20197:15 amRNSApplication to Nasdaq First North Growth Market
19th Nov 201911:05 amRNSSecond Price Monitoring Extn
19th Nov 201911:00 amRNSPrice Monitoring Extension
15th Nov 201911:06 amRNSSecond Price Monitoring Extn
15th Nov 201911:00 amRNSPrice Monitoring Extension
12th Nov 20193:45 pmRNSRegistration of Shares
8th Nov 20197:00 amRNSResults of Placing and Issue Price
7th Nov 20194:51 pmRNSProposed Placing and Financial Adviser Appointment
5th Nov 20194:40 pmRNSSecond Price Monitoring Extn
5th Nov 20194:36 pmRNSPrice Monitoring Extension
5th Nov 20192:05 pmRNSSecond Price Monitoring Extn
5th Nov 20192:00 pmRNSPrice Monitoring Extension
5th Nov 201911:05 amRNSSecond Price Monitoring Extn
5th Nov 201911:00 amRNSPrice Monitoring Extension
5th Nov 20199:05 amRNSSecond Price Monitoring Extn
5th Nov 20199:00 amRNSPrice Monitoring Extension
4th Nov 20194:35 pmRNSPrice Monitoring Extension
4th Nov 20192:05 pmRNSSecond Price Monitoring Extn
4th Nov 20192:00 pmRNSPrice Monitoring Extension
1st Nov 20192:15 pmRNSStatement regarding Price Movement
1st Nov 20192:05 pmRNSSecond Price Monitoring Extn
1st Nov 20192:00 pmRNSPrice Monitoring Extension
1st Nov 201911:06 amRNSSecond Price Monitoring Extn
1st Nov 201911:00 amRNSPrice Monitoring Extension
31st Oct 20194:35 pmRNSPrice Monitoring Extension
25th Oct 20199:27 amRNSResults of EGM
11th Oct 20192:05 pmRNSSecond Price Monitoring Extn
11th Oct 20192:00 pmRNSPrice Monitoring Extension
9th Oct 20197:00 amRNSMatins Trial Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.